Table 7.

Ongoing clinical trials assessing the efficacy of KRAS inhibitors in lung cancer.

Inhibitor	NCT number	Phase	Population	Treatment	Estimated enrollment	Primary outcome	Status
AMG 510	NCT04303780	III	Advanced/metastatic NSCLC with KRAS G12C mutation	AMG 510	650	PFS	Recruiting
MRTX849	NCT04330664	I/II	Solid tumor malignancy with KRAS G12C mutation	MRTX849	148	Safety and pharmacokinetics	Recruiting

NSCLC, non-small cell lung cancer; KRAS, kirsten rat sarcoma mutations; PFS, progression free survival.